The Immunology Core will be co-directed by Andrew Luster and Shiv Pillai. A variety of services will be provided by the Core. These include a number of novel and powerful approaches that can be applied to human immunology, for which the Core offers protocols, education, and bioinformatics analysis. In addition to these more innovative approaches, the Core also continues to provide access to established technologies such as high-speed cell sorting and cytokine assays. The services are organized into three major categories: (1) education and training, (2) routine immunology tools, and (3) specialized immunology services. By assisting investigators in developing assays and offering access to both standard techniques and a number of newly developing, powerful immunologic techniques, this core is fundamentally necessary for a number of studies pursued by CSIBD investigators and advanced trainees ready to emerge as independent investigators.
The specific aims of Immunology Core are to (1) provide CSIBD members with access to immunological resources that would otherwise be cost-prohibitive to individual researchers; (2) offer CSIBD investigators access to cutting-edge immunological techniques that are at the forefront of immunology research; and (3) promote the development of junior investigators and foster collaborations by providing a connection point between investigators of varying research approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK043351-29
Application #
9625629
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
29
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Cushing, Kelly C; Kordbacheh, Hamed; Gee, Michael S et al. (2018) Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. J Crohns Colitis :
Vatanen, Tommi; Plichta, Damian R; Somani, Juhi et al. (2018) Genomic variation and strain-specific functional adaptation in the human gut microbiome during early life. Nat Microbiol :
Su, C; Su, L; Li, Y et al. (2018) Helminth-induced alterations of the gut microbiota exacerbate bacterial colitis. Mucosal Immunol 11:144-157
Merkulova, Maria; P?unescu, Teodor G; Nair, Anil V et al. (2018) Targeted deletion of the Ncoa7 gene results in incomplete distal renal tubular acidosis in mice. Am J Physiol Renal Physiol 315:F173-F185
Burke, Kristin E; Khalili, Hamed; Garber, John J et al. (2018) Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflamm Bowel Dis 24:1840-1848
Martin, Alicia R; Karczewski, Konrad J; Kerminen, Sini et al. (2018) Haplotype Sharing Provides Insights into Fine-Scale Population History and Disease in Finland. Am J Hum Genet 102:760-775
Momozawa, Yukihide; Dmitrieva, Julia; Théâtre, Emilie et al. (2018) IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat Commun 9:2427
Vandoorne, Katrien; Rohde, David; Kim, Hye-Yeong et al. (2018) Imaging the Vascular Bone Marrow Niche During Inflammatory Stress. Circ Res 123:415-427
Cai, Tianrun; Lin, Tzu-Chieh; Bond, Allison et al. (2018) The Association Between Arthralgia and Vedolizumab Using Natural Language Processing. Inflamm Bowel Dis 24:2242-2246
Ganna, Andrea; Satterstrom, F Kyle; Zekavat, Seyedeh M et al. (2018) Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. Am J Hum Genet 102:1204-1211

Showing the most recent 10 out of 1166 publications